

DAFTAR PUSTAKA

- Adams, E. F., Todo, T., Schrell, U. M., Thierauf, P., White, M. C. & Fahlbusch, R. 1991. Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules. *Int J Cancer*, 49, 398–402.
- Alexiou, G. A., Markoula, S., Gogou, P. & Kyritsis, A. P. 2011. Genetic and molecular alterations in meningiomas. *Clin Neurol Neurosurg*, 113, 261–7.
- Andersen, B. M., Pluhar, G. E., Seiler, C. E., Goulart, M. R., Santacruz, K. S., Schutten, M. M., Meints, J. P., O'sullivan, M. G., Bentley, R. T. & Packer, R. A. 2013. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. *Cancer research*, 73, 2987–2997.
- Antinheimo, J., Sallinen, S. L., Sallinen, P., Haapasalo, H., Helin, H., Horelli-Kuitunen, N., Wessman, M., Sainio, M., Jaaskelainen, J. & Carpen, O. 2000a. Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated schwannomas studied by comparative genomic hybridization (CGH). *Acta Neurochir (Wien)*, 142, 1099–104; discussion 1104–5.
- Antinheimo, J., Sankila, R., Carpen, O., Pukkala, E., Sainio, M. & Jaaskelainen, J. 2000b. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. *Neurology*, 54, 71–6.
- Barnholtz-Sloan, J. S. & Kruchko, C. 2007. Meningiomas: causes and risk factors. *Neurosurg Focus*, 23, E2.
- Baser, M. E., Dg, R. E. & Gutmann, D. H. 2003. Neurofibromatosis 2. *Curr Opin Neurol*, 16, 27–33.
- Baxter, D. S., Orrego, A., Rosenfeld, J. V. & Mathiesen, T. 2014. An audit of immunohistochemical marker patterns in meningioma. *Journal of Clinical Neuroscience*, 21, 421–426.
- Begnami, M. D., Palau, M., Rushing, E. J., Santi, M. & Quezado, M. 2007. Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization. *Human pathology*, 38, 1345–1350.
- Belliveau, M. J., Lutchman, M., Claudio, J. O., Marineau, C. & Rouleau, G. A. 1995. Schwannomin: new insights into this member of the band 4.1 superfamily. *Biochem Cell Biol*, 73, 733–7.
- Bendszus, M., Rao, G., Burger, R., Schaller, C., Scheinemann, K., Warmuth-Metz, M., Hofmann, E., Schramm, J., Roosen, K. & Solymosi, L. 2000. Is there a benefit of preoperative meningioma embolization? *Neurosurgery*, 47, 1306–11; discussion 1311–2.
- Benson, V. S., Pirie, K., Green, J., Bull, D., Casabonne, D., Reeves, G. K., Beral, V. & Million Women Study, C. 2010. Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study. *Int J Cancer*, 127, 1692–8.
- Benson, V. S., Pirie, K., Green, J., Casabonne, D., Beral, V. & Million Women Study, C. 2008. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. *Br J Cancer*, 99, 185–190.

- Blankenstein, M. A., Van Der Meulen–Dijk, C. & Thijssen, J. H. 1987. Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods. *Clin Chim Acta*, 165, 189–95.
- Blitshteyn, S., Crook, J. E. & Jaeckle, K. A. 2008. Is there an association between meningioma and hormone replacement therapy? *J. Clin Oncol*, 26, 279–282.
- Bondy, M. & Ligon, B. L. 1996. Epidemiology and etiology of intrakranial meningiomas: a review. *J Neurooncol*, 29, 197–205.
- Bor–Shavit, E., Hammel, N., Nahum, Y., Rappaport, Z. H. & Stiebel–Kalish, H. 2015. Visual disability rates in a ten–year cohort of patients with anterior visual pathway meningiomas. *Disabil Rehabil*, 37, 958–62.
- Boulos, P. T., Dumont, A. S., Mandell, J. W. & Jane, J. A., Sr. 2001. Meningiomas of the orbit: contemporary considerations. *Neurosurg Focus*, 10, E5.
- Brown, K. D. & Hansen, M. R. 2008. Lipid raft localization of erbB2 in vestibular schwannoma and Schwann cells. *Otol Neurotol*, 29, 79–85.
- Butts, C. L., Shukair, S. A., Duncan, K. M., Bowers, E., Horn, C., Belyavskaya, E., Tonelli, L. & Sternberg, E. M. 2007. Progesterone inhibits mature rat dendritic cells in a receptor–mediated fashion. *Int Immunol*, 19, 287–96.
- Cea–Soriano, L., Blenk, T., Wallander, M. A. & Rodriguez, L. A. 2012. Hormonal therapies and meningioma: is there a link? *Cancer Epidemiol*, 36, 198–205.
- Clark, V. E., Erson–Omay, E. Z., Serin, A., Yin, J., Cotney, J., Ozduman, K., Avsar, T., Li, J., Murray, P. B., Henegariu, O., Yilmaz, S., Gunel, J. M., Carrion–Grant, G., Yilmaz, B., Grady, C., Tanrikulu, B., Bakircioglu, M., Kaymakcalan, H., Caglayan, A. O., Sencar, L., Ceyhun, E., Atik, A. F., Bayri, Y., Bai, H., Kolb, L. E., Hebert, R. M., Omay, S. B., Mishra–Gorur, K., Choi, M., Overton, J. D., Holland, E. C., Mane, S., State, M. W., Bilguvar, K., Baehring, J. M., Gutin, P. H., Piepmeier, J. M., Vortmeyer, A., Brennan, C. W., Pamir, M. N., Kilic, T., Lifton, R. P., Noonan, J. P., Yasuno, K. & Gunel, M. 2013. Genomic analysis of non–NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. *Science*, 339, 1077–80.
- Claus, E. B., Calvocoressi, L., Bondy, M. L., Wrensch, M., Wiemels, J. L. & Schildkraut, J. M. 2013. Exogenous hormone use, reproductive factors, and risk of intrakranial meningioma in females. *J Neurosurg*, 118, 649–56.
- Claus, E. B., Park, P. J., Carroll, R., Chan, J. & Black, P. M. 2008. Specific genes expressed in association with progesterone receptors in meningioma. *Cancer Res*, 68, 314–22.
- Conneely, O. M. & Jericevic, B. M. 2002. Progesterone regulation of reproductive function through functionally distinct progesterone receptor isoforms. *Rev Endocr Metab Disord*, 3, 201–9.
- Custer, B., Longstreth, W. T., Jr., Phillips, L. E., Koepsell, T. D. & Van Belle, G. 2006. Hormonal exposures and the risk of intrakranial meningioma in women: a population–based case–control study. *BMC Cancer*, 6, 152.
- De Vitis, L. R., Tedde, A., Vitelli, F., Ammannati, F., Mennonna, P., Bigozzi, U., Montali, E. & Papi, L. 1996a. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. *Hum Genet*, 97, 632–7.
- De Vitis, L. R., Tedde, A., Vitelli, F., Ammannati, F., Mennonna, P., Bono, P., Grammatico, B., Grammatico, P., Radice, P., Bigozzi, U., Montali, E. & Papi,

- supresor protein merlin and the ERM protein ezrin. *J Cell Sci*, 112 (Pt 6), 895–904.
- Guzińska–Ustymowicz, K., Pryczynicz, A., Kemon, A. & Czyżewska, J. 2009. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. *Anticancer Res.*, 29, 3049–3052.
- Hatch, E. E., Linet, M. S., Zhang, J., Fine, H. A., Shapiro, W. R., Selker, R. G., Black, P. M. & Inskip, P. D. 2005. Reproductive and hormonal factors and risk of brain tumors in adult females. *Int J Cancer*, 114, 797–805.
- Hilbig, A. & Barbosa–Coutinho, L. 1998. Meningiomas and hormonal receptors: immunohistochemical study in typical and non–typical tumors. *Arquivos de neuro–psiquiatria*, 56, 193–199.
- Houshmandi, S. S., Emnett, R. J., Giovannini, M. & Gutmann, D. H. 2009. The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2– and Src–dependent manner. *Mol Cell Biol*, 29, 1472–86.
- Jagannathan, J., Oskouian, R. J., Yeoh, H. K., Saulle, D. & Dumont, A. S. 2008. Molecular biology of unresectable meningiomas: implications for new treatments and review of the literature. *Skull Base*, 18, 173–87.
- James, M. F., Lelke, J. M., Maccollin, M., Plotkin, S. R., Stemmer–Rachamimov, A. O., Ramesh, V. & Gusella, J. F. 2008. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. *Neurobiol. Dis.*, 29, 278–292.
- Jhawar, B. S., Fuchs, C. S., Colditz, G. A. & Stampfer, M. J. 2003a. Sex steroid hormone exposures and risk for meningioma. *J Neurosurg*, 99, 848–53.
- Jhawar, B. S., Fuchs, C. S., Colditz, G. A. & Stampfer, M. J. 2003b. Sex steroid hormone exposures and risk for meningioma. *J Neurosurg.*, 99, 848–853.
- Johnson, D. R., Olson, J. E., Vierkant, R. A., Hammack, J. E., Wang, A. H., Folsom, A. R., Virnig, B. A. & Cerhan, J. R. 2011. Risk factors for meningioma in postmenopausal women: results from the Iowa Women's Health Study. *Neuro–oncology*, nor081.
- Kandemir, N. O., Aylin, E., Gün, B. D., Karadayi, N., Yurdakan, G. & Özdamar, Ş. O. 2010. Her-2/neu, estrogen and progesterone receptor expression in WHO derajat I meningiomas. *Balkan Med J.*, 2010.
- Keller, A., Ludwig, N., Backes, C., Romeike, B. F., Comtesse, N., Henn, W., Studel, W. I., Mawrin, C., Lenhof, H. P. & Meese, E. 2009. Genome wide expression profiling identifies specific deregulated pathways in meningioma. *Int J Cancer*, 124, 346–51.
- Kim, M., Park, H. J., Seol, J. W., Jang, J. Y., Cho, Y. S., Kim, K. R., Choi, Y., Lydon, J. P., Demayo, F. J. & Shibuya, M. 2013. VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. *EMBO Mol Med.*, 5, 1415–1430.
- Kimura, Y., Matsumae, M. & Tsutsumi, Y. 1998. Pericellular deposition of basement membrane material in myxoid meningioma: immunohistochemical evidence for unbalanced production of type IV collagen and laminin. *Pathol Int*, 48, 53–7.

- Kimura, Y., Saya, H. & Nakao, M. 2000. Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. *Neuropathology*, 20, 153–60.
- Knudson, A. G., Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A*, 68, 820–3.
- Korhonen, K., Auvinen, A., Lyytinen, H., Ylikorkala, O. & Pukkala, E. 2012. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland. *Am J Epidemiol.*, 175, 309–314.
- Korhonen, K., Raitanen, J., Isola, J., Haapasalo, H., Salminen, T. & Auvinen, A. 2010. Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. *Cancer Causes Control*, 21, 2149–56.
- Korhonen, K., Salminen, T., Raitanen, J., Auvinen, A., Isola, J. & Haapasalo, H. 2006. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. *Journal of neuro-oncology*, 80, 1–7.
- Krampla, W., Newrkla, S., Pfisterer, W., Jungwirth, S., Fischer, P., Leitha, T., Hruby, W. & Tragl, K. H. 2004. Frequency and risk factors for meningioma in clinically healthy 75-year-old patients: results of the Transdanube Ageing Study (VITA). *Cancer*, 100, 1208–12.
- Kros, J., De Greve, K., Van Tilborg, A., Hop, W., Pieterman, H., Avezaat, C., Lekanne Dit Deprez, R. & Zwarthoff, E. 2001. NF2 status of meningiomas is associated with tumour localization and histology. *J Pathol*, 194, 367–72.
- Lahkola, A., Salminen, T., Raitanen, J., Heinavaara, S., Schoemaker, M. J., Christensen, H. C., Feychting, M., Johansen, C., Klaeboe, L., Lonn, S., Swerdlow, A. J., Tynes, T. & Auvinen, A. 2008. Meningioma and mobile phone use—a collaborative case-control study in five North European countries. *Int J Epidemiol*, 37, 1304–13.
- Lahkola, A., Tokola, K. & Auvinen, A. 2006. Meta-analysis of mobile phone use and intracranial tumors. *Scand J Work Environ Health*, 32, 171–7.
- Lallemand, D., Manent, J., Couvelard, A., Watilliaux, A., Siena, M., Chareyre, F., Lampin, A., Niwa-Kawakita, M., Kalamarides, M. & Giovannini, M. 2009. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. *Oncogene*, 28, 854–865.
- Lambe, M., Coogan, P. & Baron, J. 1997. Reproductive factors and the risk of brain tumors: a population-based study in Sweden. *Int J Cancer*, 72, 389–93.
- Laurendeau, I., Ferrer, M., Garrido, D., D'haene, N., Ciavarelli, P., Basso, A., Vidaud, M., Bieche, I., Salmon, I. & Szijan, I. 2010. Gene expression profiling of the hedgehog signaling pathway in human meningiomas. *Mol Med*, 16, 262–70.
- Leães, C. G. S., Meurer, R. T., Coutinho, L. B., Ferreira, N. P., Pereira-Lima, J. F. S. & Da Costa Oliveira, M. 2010. Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. *Neuropathology*, 30, 44–49.
- Lee, E., Grutsch, J., Persky, V., Glick, R., Mendes, J. & Davis, F. 2006. Association of meningioma with reproductive factors. *Int. J. Cancer*, 119, 1152–1157.

- Leonhardt, S. A., Boonyaratanakornkit, V. & Edwards, D. P. 2003. Progesterone receptor transcription and non-transcription signaling mechanisms. *Steroids*, 68, 761–770.
- Liang, C.-C., Lee, T.-H. & Chang, S.-D. 2013. Effects of sex hormones on cell proliferation and apoptosis in the urinary bladder muscle of ovariectomized rat. *Taiwan J Obstet Gynecol.*, 52, 335–340.
- Loussouarn, D., Brunon, J., Avet-Loiseau, H., Campone, M. & Mosnier, J. F. 2006. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. *Hum Pathol*, 37, 415–21.
- Lutchman, M. & Rouleau, G. A. 1995. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. *Cancer Res*, 55, 2270–4.
- Martin, A. J., Hammond, C. J., Dobbs, H. J., Al-Sarraj, S. & Thomas, N. W. 2001. Spinal meningioma after treatment for Hodgkin disease. Case report. *J Neurosurg*, 95, 232–5.
- Maxwell, M., Galanopoulos, T., Neville-Golden, J. & Antoniadis, H. N. 1993. Expression of androgen and progesterone receptors in primary human meningiomas. *J Neurosurg*, 78, 456–62.
- Maxwell, M., Shih, S. D., Galanopoulos, T., Hedley-Whyte, E. T. & Cosgrove, G. R. 1998. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases. *J Neurosurg*, 88, 562–9.
- Mcclatchey, A. I. & Giovannini, M. 2005. Membrane organization and tumorigenesis—the NF2 tumor supresor, Merlin. *Genes Dev*, 19, 2265–77.
- Meng, J. J., Lowrie, D. J., Sun, H., Dorsey, E., Pelton, P. D., Bashour, A. M., Groden, J., Ratner, N. & Ip, W. 2000. Interaction between two isoforms of the NF2 tumor supresor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin. *J Neurosci Res*, 62, 491–502.
- Michaud, D. S., Bové, G., Gallo, V., Schlehofer, B., Tjønneland, A., Olsen, A., Overvad, K., Dahm, C. C., Teucher, B. & Boeing, H. 2011. Anthropometric measures, physical activity, and risk of glioma and meningioma in a large prospective cohort study. *Cancer Prev. Res.*, 4, 1385–1392.
- Michaud, D. S., Gallo, V., Schlehofer, B., Tjønneland, A., Olsen, A., Overvad, K., Dahm, C. C., Kaaks, R., Lukanova, A., Boeing, H., Schutze, M., Trichopoulou, A., Bamia, C., Kyrozis, A., Sacerdote, C., Agnoli, C., Palli, D., Tumino, R., Mattiello, A., Bueno-De-Mesquita, H. B., Ros, M. M., Peeters, P. H., Van Gils, C. H., Lund, E., Bakken, K., Gram, I. T., Barricarte, A., Navarro, C., Dorransoro, M., Sanchez, M. J., Rodriguez, L., Duell, E. J., Hallmans, G., Melin, B. S., Manjer, J., Borgquist, S., Khaw, K. T., Wareham, N., Allen, N. E., Tsilidis, K. K., Romieu, I., Rinaldi, S., Vineis, P. & Riboli, E. 2010. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. *Cancer Epidemiol Biomarkers Prev*, 19, 2562–2569.
- Nassehi, D. 2013. Intrakranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. *Dan Med J*, 60, B4626.
- Nassehi, D., Sørensen, L. P., Dyrbye, H., Thomsen, C., Juhler, M., Laursen, H. & Broholm, H. 2013. Peritumoral brain edema in angiomatous supratentorial

- meningiomas: an investigation of the vascular endothelial growth factor A pathway. *Apmis*, 121, 1025–1036.
- Nguyen, R., Reczek, D. & Bretscher, A. 2001. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. *J Biol Chem*, 276, 7621–9.
- Norden, A. D., Drappatz, J. & Wen, P. Y. 2007. Targeted drug therapy for meningiomas.
- Ongaratti, B., Silva, C., Trott, G., Haag, T., Leães, C., Ferreira, N., Oliveira, M. & Pereira-Lima, J. 2016. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor derajat and recurrence. *Braz. J. Med. Biol. Res.*, 49.
- Otsuka, S., Tamiya, T., Ono, Y., Michiue, H., Kurozumi, K., Daido, S., Kambara, H., Date, I. & Ohmoto, T. 2004. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intrakranial meningiomas. *J. Neurooncol.*, 70, 349–357.
- Ozer, O., Sahin, F. I., Aydemir, F., Ozen, O., Yilmaz, Z. & Altinors, N. 2009. Her-2/neu gene amplification in paraffin-embedded tissue sections of meningioma patients. *Turk Neurosurg*, 19, 135–8.
- Paek, S. H., Kim, D. G., Park, C. K., Phi, J. H., Kim, Y. Y., Im, S. Y., Kim, J. E., Park, S. H. & Jung, H. W. 2006. The role of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in microcystic meningiomas. *Oncol Rep*, 16, 49–56.
- Parry, D. M., Eldridge, R., Kaiser-Kupfer, M. I., Bouzas, E. A., Pikus, A. & Patronas, N. 1994. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. *Am J Med Genet*, 52, 450–61.
- Pearson, M. A., Reczek, D., Bretscher, A. & Karplus, P. A. 2000. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. *Cell*, 101, 259–70.
- Perry, A. 2004. Unmasking the secrets of meningioma: a slow but rewarding journey. *Surg Neurol*, 61, 171–3.
- Perry, A., Cai, D. X., Scheithauer, B. W., Swanson, P. E., Lohse, C. M., Newsham, I. F., Weaver, A. & Gutmann, D. H. 2000. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. *J Neuropathol Exp Neurol*, 59, 872–9.
- Pham, M. H., Zada, G., Mosich, G. M., Chen, T. C., Giannotta, S. L., Wang, K. & Mack, W. J. 2011. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. *Neurosurg Focus*, 30, E7.
- Pravdenkova, S., Al-Mefty, O., Sawyer, J. & Husain, M. 2006. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. *J Neurosurg*, 105, 163–73.
- Preston-Martin, S., Monroe, K., Lee, P. J., Bernstein, L., Kelsey, J., Henderson, S., Forrester, D. & Henderson, B. 1995. Spinal meningiomas in women in Los

- Angeles County: investigation of an etiological hypothesis. *Cancer Epidemiol Biomarkers Prev*, 4, 333–9.
- Preusser, M., Hassler, M., Birner, P., Rudas, M., Acker, T., Plate, K. H., Widhalm, G., Knosp, E., Breitschopf, H. & Berger, J. 2011. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. *Clin Neuropathol.*, 31, 352–360.
- Repacholi, M. H., Lerchl, A., Roosli, M., Sienkiewicz, Z., Auvinen, A., Breckenkamp, J., D'inzeo, G., Elliott, P., Frei, P., Heinrich, S., Lagroye, I., Lahkola, A., McCormick, D. L., Thomas, S. & Vecchia, P. 2012. Systematic review of wireless phone use and brain cancer and other head tumors. *Bioelectromagnetics*, 33, 187–206.
- Riemenschneider, M. J., Perry, A. & Reifenberger, G. 2006. Histological classification and molecular genetics of meningiomas. *Lancet Neurol*, 5, 1045–54.
- Robb, V. A., Li, W., Gascard, P., Perry, A., Mohandas, N. & Gutmann, D. H. 2003. Identification of a third Protein 4.1 tumor supresor, Protein 4.1R, in meningioma pathogenesis. *Neurobiol Dis*, 13, 191–202.
- Roser, F., Nakamura, M., Bellinzona, M., Rosahl, S. K., Ostertag, H. & Samii, M. 2004. The prognostic value of progesterone receptor status in meningiomas. *J Clin Pathol*, 57, 1033–7.
- Rothman, K. J., Greenland, S. & Lash, T. L. 2008. *Modern epidemiology*, Lippincott Williams & Wilkins.
- Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B. & Et Al. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. *Nature*, 363, 515–21.
- Santarius, T., Jian, B. J., Englot, D. & Mcdermott, M. W. 2014. Delayed neurological deficit following resection of tuberculum sellae meningioma: report of two cases, one with permanent and one with reversible visual impairment. *Acta Neurochir (Wien)*, 156, 1099–102.
- Schlehofer, B., Blettner, M., Preston-Martin, S., Niehoff, D., Wahrendorf, J., Arslan, A., Ahlbom, A., Choi, W. N., Giles, G. G., Howe, G. R., Little, J., Menegoz, F. & Ryan, P. 1999. Role of medical history in brain tumour development. Results from the international adult brain tumour study. *Int J Cancer*, 82, 155–60.
- Sherman, L., Xu, H. M., Geist, R. T., Saporito-Irwin, S., Howells, N., Ponta, H., Herrlich, P. & Gutmann, D. H. 1997. Interdomain binding mediates tumor growth suppression by the NF2 gene product. *Oncogene*, 15, 2505–9.
- Shimizu, T., Seto, A., Maita, N., Hamada, K., Tsukita, S. & Hakoshima, T. 2002. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. *J Biol Chem*, 277, 10332–6.
- Skiriute, D., Tamasauskas, S., Asmoniene, V., Saferis, V., Skauminas, K., Deltuva, V. & Tamasauskas, A. 2011. Tumor derajat-related NDRG2 gene expression in primary and recurrent intrakranial meningiomas. *J Neurooncol*, 102, 89–94.
- Taberner, M., Jara-Acevedo, M., Nieto, A. B., Caballero, A. R., Otero, Á., Sousa, P., Gonçalves, J., Domingues, P. H. & Orfao, A. 2013. Association between

- mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomas. *BMC Med Genet.*, 14, 114.
- Taghipour, M., Rakei, S., Monabati, A. & Nahavandinejad, M. 2007. The role of estrogen and progesterone receptors in grading of the malignancy of meningioma. *Iran Red Crescent Med J.*, 2007, 17–21.
- Tikoo, A., Varga, M., Ramesh, V., Gusella, J. & Maruta, H. 1994. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). *J Biol Chem*, 269, 23387–90.
- Todo, T., Adams, E. F. & Fahlbusch, R. 1993. Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation. *J Neurosurg*, 78, 463–9.
- Turbin, R. E. & Pokorny, K. 2004. Diagnosis and treatment of orbital optic nerve sheath meningioma. *Cancer Control*, 11, 334–41.
- Vadivelu, S. & Schulder, M. 2012. Intrakranial Meningiomas: Role of Exogenous Hormones. In: HAYAT, M. A. (ed.) *Tumors of the Central Nervous System, Volume 7: Meningiomas and Schwannomas*. New York: Springer.
- Vernooij, M. W., Ikram, M. A., Tanghe, H. L., Vincent, A. J., Hofman, A., Krestin, G. P., Niessen, W. J., Breteler, M. M. & Van Der Lugt, A. 2007. Incidental findings on brain MRI in the general population. *N Engl J Med*, 357, 1821–8.
- Wahab, M. & Al-Azzawi, F. 2003. Meningioma and hormonal influences. *Climacteric*, 6, 285–92.
- Wang, B., Cui, Z., Zhong, Z., Sun, Y., Yang, G. Y., Sun, Q. & Bian, L. 2016. The role and regulatory mechanism of IL-1 β on the methylation of the NF2 gene in benign meningiomas and leptomeninges. *Mol Carcinog.* 55(12), pp.2268–2277.
- Wellenreuther, R., Kraus, J. A., Lenartz, D., Menon, A. G., Schramm, J., Louis, D. N., Ramesh, V., Gusella, J. F., Wiestler, O. D. & Von Deimling, A. 1995. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. *Am J Pathol*, 146, 827–32.
- Wiemels, J., Wrensch, M. & Claus, E. B. 2010. Epidemiology and etiology of meningioma. *J Neurooncol*, 99, 307–14.
- Wigertz, A., Lonn, S., Hall, P., Auvinen, A., Christensen, H. C., Johansen, C., Klæboe, L., Salminen, T., Schoemaker, M. J., Swerdlow, A. J., Tynes, T. & Feychting, M. 2008. Reproductive factors and risk of meningioma and glioma. *Cancer Epidemiol Biomarkers Prev*, 17, 2663–70.
- Wigertz, A., Lonn, S., Mathiesen, T., Ahlbom, A., Hall, P., Feychting, M. & Swedish Interphone Study, G. 2006. Risk of brain tumors associated with exposure to exogenous female sex hormones. *Am J Epidemiol*, 164, 629–36.
- Wozniak, K., Piaskowski, S., Gresner, S. M., Golanska, E., Bieniek, E., Bigoszewska, K., Sikorska, B., Szybka, M., Kulczycka-Wojdala, D., Zakrzewska, M., Zawlik, I., Papierz, W., Stawski, R., Jaskolski, D. J., Och, W., Sieruta, M., Liberski, P. P. & Rieske, P. 2008. BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. *Cancer Genet Cytogenet*, 183, 14–20.
- Xiao, G. H., Beeser, A., Chernoff, J. & Testa, J. R. 2002. p21-activated kinase links Rac/Cdc42 signaling to merlin. *J Biol Chem*, 277, 883–6.

